Andere talen Regeneron Pharmaceuticals, Inc. Sao Paulo

Aandelen

REGN34

BRREGNBDR005

Beurs gesloten - Sao Paulo Andere beurzen 16:57:17 02-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
98,11 ^BRL	-1,40%		+1,67%	+44,05%

10:25	Regeneron, Sanofi zeggen dat behandeling voor chronische obstructieve longziekte Europese goedkeuring krijgt	MT
07:45	Sanofi krijgt EU-goedkeuring voor Dupixent	RE

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval	10:25
Sanofi-Blockbuster Dupixent: Zulassung in Europa für spezielle Lungenkrankheit	08:16
Sanofi obteint l'approbation de L'UE pour le Dupixent	07:45
Sanofi erhält EU-Zulassung für Dupixent als COPD-Therapie	07:40
Sanofi, Regeneron Get EU Approval for Dupixent to Treat Respiratory Disease	07:38
EU approves Sanofi's Dupixent for 'smoker's lungs'	07:00
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD	07:00
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD	07:00
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,190,564, According to a Recent SEC Filing	02/07
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm	02/07
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN	02/07
REGENERON - ODRONEXTAMAB RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT RELAPSED, REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA	01/07
Regeneron Gets European Health Agency Committee's Positive Opinion for Conditional Marketing Authorization of Lymphoma Drug Candidate Odronextamab	28/06
Regeneron Wins CHMP Backing of Lymphoma Drug Odronextamab	28/06
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma	28/06
Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma	28/06
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024	27/06
ETF de la semana: Invertir en Europa fuera de Francia para evitar el riesgo político	27/06
Sanofi - Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM	27/06
Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study	27/06

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Regeneron Pharmaceuticals, Inc. Sao Paulo

Aandelen

REGN34

BRREGNBDR005

Andere talen

Filters